|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003440,
umls-concept:C0019134,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0030705,
umls-concept:C0035173,
umls-concept:C0040018,
umls-concept:C0079411,
umls-concept:C0149871,
umls-concept:C0254657,
umls-concept:C0380191,
umls-concept:C0443199,
umls-concept:C1149593,
umls-concept:C1883254
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1999-8-4
|
|
pubmed:abstractText |
Direct thrombin inhibitors belong to a new class of antithrombotic drugs whose effects on blood coagulation in vivo in patients suffering from acute thrombotic conditions have not yet been fully explored.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0340-6245
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
498-501
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
|
|
pubmed:affiliation |
Division of Angiology and Hemostasis, University Hospital of Geneva, Switzerland. bounamea@cmu.unige.ch
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
